|
|
ChemGenics Pharmaceuticals |
Genetically directed drug discovery focused on fungal bacterial diseases |
Acquired |
1997 |
 |
|
|
 |
Developer of high-technology purification, analysis and synthesis products |
Acquired |
1998 |
 |
|
|
 |
Discovering, developing and commercializing cancer therapeutics. |
IPO |
2010 |
|
|
|
 |
Novel cardiovascular tests to address significant unmet medical needs, improve patient outcomes and reduce healthcare costs. |
IPO |
2011 |
|
|
|
 |
Innovative genetic analysis technologies for the development and marketing of molecular diagnostics tests. |
IPO |
2007 |
|
|
|
 |
Discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases. |
IPO |
2005 |
|
|
|
 |
Developing therapeutic candidates for the treatment of immune and metabolic diseases. |
IPO |
2013 |
|
|
|
 |
Creating novel antibiotics for serious and life-threatening multi-drug resistant infections. |
IPO |
2013 |
|
|
|
 |
Discovery, development and commercialization of prescription pain management products |
IPO |
2000 |
|
|
|
 |
Pharmaceuticals for treatment of metabolic diseases and endocrine disorders |
IPO |
2000 |
|
|
|
 |
Products that enhance the ability of veterinarians to economically provide advanced medical care |
IPO |
1991 |
|
|
|
 |
Design, development, manufacturing, and marketing of medical devices focused on women's health |
IPO |
1996 |
|
|
|
 |
Technology and products to treat cancers, infectious diseases, and autoimmune disorders |
IPO |
2000 |
|
|
|
 |
Sequenced human genome; now focused on therapeutics for cancer and other diseases |
IPO |
2000 |
|
|
|
 |
Proprietary technologies for the early detection, monitoring and staging of common cancers |
IPO |
2001 |
|
|
|
 |
Discovery, development and commercialization of druts to treat neurological diseases and disorders |
IPO |
2004 |
|
